Chao Zhang1, Richard Kimura2, Lotfi Abou-Elkacem2, Jelena Levi2, Lingyun Xu2, Sanjiv Sam Gambhir3. 1. Department of Radiology, Molecular Imaging Program at Stanford, Canary Center for Cancer Early Detection, Stanford University, Stanford, California; and Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Department of Radiology, Molecular Imaging Program at Stanford, Canary Center for Cancer Early Detection, Stanford University, Stanford, California; and. 3. Department of Radiology, Molecular Imaging Program at Stanford, Canary Center for Cancer Early Detection, Stanford University, Stanford, California; and sgambhir@stanford.edu.
Abstract
Photoacoustic imaging is a nonionizing biomedical imaging modality with higher resolution and imaging depth than fluorescence imaging, which has greater sensitivity. The combination of the 2 imaging modalities could improve the detection of cancer. Integrin αvβ6 is a cell surface marker overexpressed in many different cancers. Here, we report the development and evaluation of a dye-labeled cystine knot peptide, which selectively recognizes integrin αvβ6 with high affinity, for photoacoustic and fluorescence imaging. The new dual-modality probe may find clinical application in cancer diagnosis and intraoperative imaging of integrin αvβ6-positive tumors. METHODS: An engineered cystine knot peptide, R01, that recognizes integrin αvβ6 was labeled with Atto 740 (A740) and evaluated for its specific cell uptake and its sensitivity threshold. A740-R01 was injected via the tail vein into nude mice xenografted with A431 (integrin αvβ6-positive) or 293T (integrin αvβ6-negative) tumors. Photoacoustic and fluorescence scans of tumors were acquired before and at 0.5, 1, 2, and 4 h after injection of A740-R01. Dynamic photoacoustic scans of various normal organs were also acquired. Ex vivo fluorescence imaging of tissues was performed 1 h after injection. RESULTS: The A740-R01 demonstrated integrin αvβ6-dependent binding to A431 cells in culture. Sensitivity studies indicated that the probe may potentially detect lesions as small as 1 or 6 mm3 by fluorescence or photoacoustic imaging, respectively. The photoacoustic and fluorescence signals of A431 xenografts at 1 h after injection were 1.87 ± 0.25 arbitrary units (AU) and 8.27 ± 0.87 AU, respectively. Target specificity was confirmed by low tumor uptake in 293T tumors at 1 h after injection (1.07 ± 0.15 AU and 1.10 ± 0.14 AU for photoacoustic and fluorescence signals, respectively). A740-R01 exhibited hepatobiliary clearance marked by high uptake in the liver, spleen, and intestine but low uptake in the kidneys. CONCLUSION: A740-R01 specifically targeted integrin αvβ6 with low nanomolar affinity. A740-R01 was able to detect integrin αvβ6 both in vitro and in vivo by photoacoustic and fluorescence imaging. A740-R01 is able to detect αvβ6-positive tumors in living subjects and may have clinical application in cancer diagnosis and real-time image-guided surgery.
Photoacoustic imaging is a nonionizing biomedical imaging modality with higher resolution and imaging depth than fluorescence imaging, which has greater sensitivity. The combination of the 2 imaging modalities could improve the detection of cancer. Integrin αvβ6 is a cell surface marker overexpressed in many different cancers. Here, we report the development and evaluation of a dye-labeled cystine knot peptide, which selectively recognizes integrin αvβ6 with high affinity, for photoacoustic and fluorescence imaging. The new dual-modality probe may find clinical application in cancer diagnosis and intraoperative imaging of integrin αvβ6-positive tumors. METHODS: An engineered cystine knot peptide, R01, that recognizes integrin αvβ6 was labeled with Atto 740 (A740) and evaluated for its specific cell uptake and its sensitivity threshold. A740-R01 was injected via the tail vein into nude mice xenografted with A431 (integrin αvβ6-positive) or 293T (integrin αvβ6-negative) tumors. Photoacoustic and fluorescence scans of tumors were acquired before and at 0.5, 1, 2, and 4 h after injection of A740-R01. Dynamic photoacoustic scans of various normal organs were also acquired. Ex vivo fluorescence imaging of tissues was performed 1 h after injection. RESULTS: The A740-R01 demonstrated integrin αvβ6-dependent binding to A431 cells in culture. Sensitivity studies indicated that the probe may potentially detect lesions as small as 1 or 6 mm3 by fluorescence or photoacoustic imaging, respectively. The photoacoustic and fluorescence signals of A431 xenografts at 1 h after injection were 1.87 ± 0.25 arbitrary units (AU) and 8.27 ± 0.87 AU, respectively. Target specificity was confirmed by low tumor uptake in 293T tumors at 1 h after injection (1.07 ± 0.15 AU and 1.10 ± 0.14 AU for photoacoustic and fluorescence signals, respectively). A740-R01 exhibited hepatobiliary clearance marked by high uptake in the liver, spleen, and intestine but low uptake in the kidneys. CONCLUSION: A740-R01 specifically targeted integrin αvβ6 with low nanomolar affinity. A740-R01 was able to detect integrin αvβ6 both in vitro and in vivo by photoacoustic and fluorescence imaging. A740-R01 is able to detect αvβ6-positive tumors in living subjects and may have clinical application in cancer diagnosis and real-time image-guided surgery.
Authors: N Ahmed; F Pansino; Riley Clyde; P Murthi; M A Quinn; G E Rice; M V Agrez; S Mok; M S Baker Journal: Carcinogenesis Date: 2002-02 Impact factor: 4.944
Authors: E Patsenker; L Wilkens; V Banz; C H Osterreicher; R Weimann; S Eisele; A Keogh; D Stroka; A Zimmermann; F Stickel Journal: J Hepatol Date: 2010-01-13 Impact factor: 25.083
Authors: B Sipos; D Hahn; A Carceller; J Piulats; J Hedderich; H Kalthoff; S L Goodman; M Kosmahl; G Klöppel Journal: Histopathology Date: 2004-09 Impact factor: 5.087
Authors: Jonathan L Hecht; Brian M Dolinski; Humphrey A Gardner; Shelia M Violette; Paul H Weinreb Journal: Appl Immunohistochem Mol Morphol Date: 2008-12
Authors: Moritz F Kircher; Adam de la Zerda; Jesse V Jokerst; Cristina L Zavaleta; Paul J Kempen; Erik Mittra; Ken Pitter; Ruimin Huang; Carl Campos; Frezghi Habte; Robert Sinclair; Cameron W Brennan; Ingo K Mellinghoff; Eric C Holland; Sanjiv S Gambhir Journal: Nat Med Date: 2012-04-15 Impact factor: 53.440
Authors: Bo Wang; Jimmy L Su; James Amirian; Silvio H Litovsky; Richard Smalling; Stanislav Emelianov Journal: Opt Express Date: 2010-03-01 Impact factor: 3.894
Authors: Willemieke S Tummers; Juergen K Willmann; Bert A Bonsing; Alexander L Vahrmeijer; Sanjiv S Gambhir; Rutger-Jan Swijnenburg Journal: Pancreas Date: 2018-07 Impact factor: 3.327
Authors: Anne C Conibear; Sonja Hager; Josef Mayr; Matthias H M Klose; Bernhard K Keppler; Christian R Kowol; Petra Heffeter; Christian F W Becker Journal: Bioconjug Chem Date: 2017-08-10 Impact factor: 4.774
Authors: Richard H Kimura; Ling Wang; Bin Shen; Li Huo; Willemieke Tummers; Fabian V Filipp; Haiwei Henry Guo; Thomas Haywood; Lotfi Abou-Elkacem; Lucia Baratto; Frezghi Habte; Rammohan Devulapally; Timothy H Witney; Yan Cheng; Suhas Tikole; Subhendu Chakraborti; Jay Nix; Christopher A Bonagura; Negin Hatami; Joshua J Mooney; Tushar Desai; Scott Turner; Richard S Gaster; Andrea Otte; Brendan C Visser; George A Poultsides; Jeffrey Norton; Walter Park; Mark Stolowitz; Kenneth Lau; Eric Yang; Arutselvan Natarajan; Ohad Ilovich; Shyam Srinivas; Ananth Srinivasan; Ramasamy Paulmurugan; Juergen Willmann; Frederick T Chin; Zhen Cheng; Andrei Iagaru; Fang Li; Sanjiv S Gambhir Journal: Nat Commun Date: 2019-10-14 Impact factor: 14.919